MARY LINN: Open Payments
NPI 1013149798 · VAN BUREN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$990 in 59 payments from 13 companies in 2025. Trend: 2023 $1,169 · 2024 $1,116 · 2025 $990
Food & beverage: $990
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $205 |
| Amgen Inc. | 14 | $189 |
| AstraZeneca Pharmaceuticals LP | 6 | $106 |
| Novo Nordisk Inc | 5 | $94 |
| Sumitomo Pharma America, Inc. | 5 | $81 |
| Antares Pharma, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $54 |
| PFIZER INC. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
Products named: OTEZLA, QULIPTA, GEMTESA, UBRELVY, AIRSUPRA, XYOSTED, Ozempic, REXULTI.
Industry payments across AR — which companies pay providers there.
